Ajanta Pharma Announces Launch of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension
Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces the launch of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension, a bioequivalent prescription generic version of Zegerid® Powder for Oral Suspension (20mg/1680mg and 40mg/1680mg), into the US market.
Omeprazole and Sodium Bicarbonate Powder for Oral Suspension is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Applications (ANDAs) of which it has 14 final ANDA approvals; 2 tentative approvals; and 10 ANDAs under review with the United States Food & Drug Administration.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd